Michel Detheux - Mar 7, 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Mar 7, 2025
Transactions value $
$0
Form type
4
Date filed
3/11/2025, 08:00 PM
Previous filing
Aug 9, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Award $0 +77K +130.72% $0.00 136K Mar 7, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +459K $0.00 459K Mar 7, 2025 Common Stock 459K $7.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The shares of common stock underlying the RSUs will vest over 4 years: 25% will vest on March 7, 2026 and the remainder will vest equally, on an annual basis, over the remaining 3 years, subject to the reporting person's continued service to the issuer.
F2 This stock option shall vest over four years, with 25% vesting on March 7, 2026 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the issuer.